Subscribe to RSS
DOI: 10.1055/s-0029-1245487
© Georg Thieme Verlag KG Stuttgart · New York
Prognostische Faktoren beim chronisch-diabetischen Makulaödem nach intravitrealer Therapie
Prognostic Factors for Visual Outcome after Intravitreal Drug Therapy for Chronic Diabetic Macular OedemaPublication History
Eingegangen: 18.3.2010
Angenommen: 13.5.2010
Publication Date:
01 July 2010 (online)

Zusammenfassung
Hintergrund: Seit wenigen Jahren wird zunehmend Bevacizumab und Triamcinolonazetat (TA) zur Behandlung des diabetischen Makulaödems intravitreal eingesetzt. Es ist jedoch ungeklärt, welche Patienten davon profitieren. In dieser Studie untersuchen wir Faktoren, die das Visuslangzeitergebnis nach intravitrealen Injektionen bei DMÖ beeinflussen. Methoden: Es wurden 50 Augen (37 Patienten) analysiert, die bei diabetischem Makulaödem mit intravitrealem Bevacizumab, Triamcinolon oder beidem behandelt wurden und eine Mindest-Nachbeobachtungszeit von 6 Monaten hatten. Ausgewertet wurden klinische, angiografische und OCT-Befunde. Ergebnisse: Nach einer mittleren Beobachtungszeit von 14,6 ± 6 Monaten stieg der Visus bei 22 Augen signifikant an und fiel bei 28 Augen ab. Das Vorliegen eines, im OCT sichtbaren zystoiden Makulaödems korrelierte mit einem ungünstigen Visuslangzeitergebnis (p < 0,001), wohingegen ein frühes Ansprechen (nach 5 Wochen) auf die Therapie mit einer Visusverbesserung (p = 0,016) verbunden war. Die initiale zentrale Makuladicke im OCT, die Art des Wirkstoffs bei Monotherapie, Alter und Geschlecht hatten keinen Einfluss auf das Visuslangzeitergebnis. Schlussfolgerung: Bei initialem zystoidem diabetischem Makulaödem ist die Visusprognose ungünstig. Eine intravitreale Behandlung sollte vor Entwicklung eines zystoiden Makulaödems begonnen werden, da dann ein Ansprechen auf die Therapie schon bei einer niedrigen Zahl von Injektionen wahrscheinlich ist. Ein frühes Ansprechen auf die Therapie ist ein guter Vorhersageparameter für einen guten Endvisus.
Abstract
Background: In recent years, intravitreal bevacizumab and triamcinolone acetonide (TA) have been widely used to treat diabetic macular oedema (DMO). However, the indication criteria are not clear. The purpose of this study was to evaluate factors which are decisive for long-term visual outcome after intravitreal drug treatment for eyes with DMO. Materials and Methods: Fifty eyes (37 patients) treated with intravitreal bevacizumab, TA, or sequentially with both for DMO with a minimum follow-up period of 6 months were analysed retrospectively. The eyes with an increase of best-corrected visual acuity (BCVA) at the last visit were classified as gainers, and eyes with stable or decreased BCVA as non-gainers. Clinical and imaging findings were evaluated. Results: BCVA significantly increased in 22 eyes and decreased in 28 eyes after a mean follow-up period of 14.6 ± 6 months after initial intravitreal intervention. Unfavourable for the long-term visual outcome was the presence of cystoid macular oedema (CMO, p < 0.001), whereas an early response at 5 weeks into therapy indicated a positive outcome (p = 0.016). The initial central macular thickness measured by OCT, the type of agent used in monotherapy, age and gender were without influence on long-term visual acuity. Conclusions: An initial CMO is unfavourable for the prognosis of long-term visual outcome of DMO. Hence, benefit from intravitreal treatment with bevacizumab and/or TA is more likely in the early stages of chronic DMO before CMO has evolved. In eyes without CMO even a low number of injections is beneficial. An early response following intravitreal bevacizumab or TA is a predictor of long-term benefit.
Schlüsselwörter
Bevacizumab - Triamcinolonazetat - zystoides Makulaödem - diabetisches Makulaödem - Prognose
Key words
bevacizumab - triamcinolone acetate - cystoid macular oedema - diabetic macular oedema - prognosis
Literatur
- 1
Klein R, Klein B E, Moss S E et al.
The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.
Ophthalmology.
1984;
91
1464-1474
MissingFormLabel
- 2
Sander B, Hamann P, Larsen M.
A 5-year follow-up of photocoagulation in diabetic macular edema: the prognostic value
of vascular leakage for visual loss.
Graefes Arch Clin Exp Ophthalmol.
2008;
246
1535-1539
MissingFormLabel
- 3
Beck R W, Edwards A R, Aiello L P et al.
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and
intravitreal triamcinolone for diabetic macular edema.
Arch Ophthalmol.
2009;
127
245-251
MissingFormLabel
- 4
Cantrill H L.
The diabetic retinopathy study and the early treatment diabetic retinopathy study.
Int Ophthalmol Clin.
1984;
24
13-29
MissingFormLabel
- 5
Lovestam-Adrian M, Agardh E.
Photocoagulation of diabetic macular oedema – complications and visual outcome.
Acta Ophthalmol Scand.
2000;
78
667-671
MissingFormLabel
- 6
Williams B, Gallacher B, Patel H et al.
Glucose-induced protein kinase C activation regulates vascular permeability factor
mRNA expression and peptide production by human vascular smooth muscle cells in vitro.
Diabetes.
1997;
46
1497-1503
MissingFormLabel
- 7
Lam D S, Lai T Y, Lee V Y et al.
Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema:
six-month results of a randomized controlled trial.
Retina.
2009;
29
292-299
MissingFormLabel
- 8
Gillies M C, Sutter F K, Simpson J M et al.
Intravitreal triamcinolone for refractory diabetic macular edema: two-year results
of a double-masked, placebo-controlled, randomized clinical trial.
Ophthalmology.
2006;
113
1533-1538
MissingFormLabel
- 9
Paccola L, Costa R A, Folgosa M S et al.
Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic
macular oedema (IBEME study).
Br J Ophthalmol.
2008;
92
76-80
MissingFormLabel
- 10
Shimura M, Nakazawa T, Yasuda K et al.
Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide
on persistent diffuse diabetic macular edema.
Am J Ophthalmol.
2008;
145
854-861
MissingFormLabel
- 11
Soheilian M, Ramezani A, Obudi A et al.
Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone
versus macular photocoagulation in diabetic macular edema.
Ophthalmology.
2009;
116
1142-1150
MissingFormLabel
- 12
Arevalo J F, Sanchez J G, Fromow-Guerra J et al.
Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse
diabetic macular edema: results from the Pan-American Collaborative Retina Study Group
(PACORES) at 12-month follow-up.
Graefes Arch Clin Exp Ophthalmol.
2009;
247
735-743
MissingFormLabel
- 13
Kook D, Wolf A, Kreutzer T et al.
Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse
diabetic macular edema.
Retina.
2008;
28
1053-1060
MissingFormLabel
- 14
Soliman W, Sander B, Jorgensen T M.
Enhanced optical coherence patterns of diabetic macular oedema and their correlation
with the pathophysiology.
Acta Ophthalmol Scand.
2007;
85
613-617
MissingFormLabel
- 15
Kang S W, Park C Y, Ham D I.
The correlation between fluorescein angiographic and optical coherence tomographic
features in clinically significant diabetic macular edema.
Am J Ophthalmol.
2004;
137
313-322
MissingFormLabel
- 16
Jaissle G B, Szurman P, Bartz-Schmidt K U.
Recommendation for the implementation of intravitreal injections – statement of the
German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional
Association of Ophthalmologists (BVA).
Klin Monatsbl Augenheilkd.
2005;
222
390-395
MissingFormLabel
- 17
Yanoff M, Fine B S, Brucker A J et al.
Pathology of human cystoid macular edema.
Surv Ophthalmol.
1984;
28 Suppl
505-511
MissingFormLabel
- 18
Bringmann A, Reichenbach A, Wiedemann P.
Pathomechanisms of cystoid macular edema.
Ophthalmic Res.
2004;
36
241-249
MissingFormLabel
- 19
Lardenoye C W, Probst K, DeLint P J et al.
Photoreceptor function in eyes with macular edema.
Invest Ophthalmol Vis Sci.
2000;
41
4048-4053
MissingFormLabel
- 20
Coscas G, Gaudric A.
Natural course of nonaphakic cystoid macular edema.
Surv Ophthalmol.
1984;
28 Suppl
471-484
MissingFormLabel
- 21
Audren F, Erginay A, Haouchine B et al.
Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month
results of a prospective controlled trial.
Acta Ophthalmol Scand.
2006;
84
624-630
MissingFormLabel
- 22
Soliman W, Sander B, Soliman K A et al.
The predictive value of optical coherence tomography after grid laser photocoagulation
for diffuse diabetic macular oedema.
Acta Ophthalmol.
2008;
86
284-291
MissingFormLabel
- 23
Brasil O F, Smith S D, Galor A et al.
Predictive factors for short-term visual outcome after intravitreal triamcinolone
acetonide injection for diabetic macular oedema: an optical coherence tomography study.
Br J Ophthalmol.
2007;
91
761-765
MissingFormLabel
- 24
Avitabile T, Longo A, Reibaldi A.
Intravitreal triamcinolone compared with macular laser grid photocoagulation for the
treatment of cystoid macular edema.
Am J Ophthalmol.
2005;
140
695-702
MissingFormLabel
- 25
Kim J E, Pollack J S, Miller D G et al.
ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection
study for refractory diabetic macular edema.
Retina.
2008;
28
735-740
MissingFormLabel
- 26
Pournaras J A, Erginay A, Lazrak Z et al.
Spectral domain optical coherence tomography in diabetic macular edema.
Ophthalmic Surg Lasers Imaging.
2009;
40
548-553
MissingFormLabel
- 27
Rosenfeld P J, Moshfeghi A A, Puliafito C A.
Optical coherence tomography findings after an intravitreal injection of bevacizumab
(avastin) for neovascular age-related macular degeneration.
Ophthalmic Surg Lasers Imaging.
2005;
36
331-335
MissingFormLabel
Dr. Rainer Guthoff
Augenklinik, Universität Würzburg
Josef-Schneider-Str. 11
97080 Würzburg
Phone: ++ 49/9 31/20 12 03 51
Fax: ++ 49/9 31/20 12 04 91
Email: r.guthoff@uni-wuerzburg.de